Scott Nelson, left, and Nathaniel Kallmyer work in the laboratory of Zymosense, a startup company based in the Iowa State ...

With climate change and higher incidences of crop diseases, global cocoa production and supply is being threatened. A ...

Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME ...

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

The Global Precision Fermentation Market Size projected to grow at a CAGR of 40.1% from 2026 to 2032, according to a new ...

Researchers in Singapore have developed two natural methods for carob flavour enhancement, improving its suitability for ...

With climate change and higher incidence of crop diseases, global cocoa production and supply is being threatened. A research team from the National ...

Carob choc 1Assoc Prof Liu Shao Quan (left) and Mr Manfred Ku from the NUS Department of Food Science and Technology ...

RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging ...

Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug. At the heart of the deal is brelovitug, an immunoglobulin G1 monoclonal ...

Kamada ends its Phase 3 inhaled AAT trial after a futility analysis but maintains 2025 guidance and forecasts double-digit growth in 2026.

Denali's validated platform, strategic pipeline, and experienced management present a compelling long-term investment opportunity. Find out why DNLI stock is a Buy.